A study in humans identified the miR-6742-5p as downregulated in whole blood of patients with recurrent myocardial infarction after percutaneous coronary intervention compared to stable patients, with this differential expression remaining significant after false-discovery rate correction in a replication cohort, indicating its potential as a biomarker for thrombotic risk in coronary artery disease [Onuoha et al. DOI:10.1111/cts.13307].